can begin marketing their new radiation dosing monitor that can be implanted in the human body near the cancer that is being treated.

On Monday, Sicel said it had received approval from the U.S. Food and Drug Administration to begin marketing its DVS or dose verification system.

The implantable dosimeter is designed to be implanted near tumor sites in breast and prostate cancer patients who are receiving external radiation therapy.

The addition to Sicel’s product line is designed for use with hypo-fractionated therapy (HVT) which delivers higher doses of radiation in fewer treatments.

“The is an important advance in hypo-fractionated therapy, because physicians can now confidently determine the prescribed dose has been accurately delivered throughout the course of treatment, which is a key determinant in the long-term successful treatment of a tumor,” said Arnold Malcolm, associate professor Vanderbilt Center for Radiation Oncology in a statement issued by Sicel. “This device may actually accelerate the use of hypo-fractionated protocols, like those being adopted for treatment of prostate cancer, which may offer benefits across the healthcare spectrum.”